Answers are grounded in this paper and cite their sources.
Prospective study shows PSMA PET/CT reclassifies metastatic stage in high-risk prostate cancer, suggesting improved treatment decisions.
Radiolabeled prostate-specific membrane antigen (PSMA) PET/CT has demonstrated superior diagnostic accuracy for staging prostate cancer (PC) compared with conventional imaging modalities. However, the clinical impact of replacing ¹⁸F-NaF PET/CT with PSMA PET/CT in high-risk PC remains underexplored. Methods: In this prospective single-center study, 160 patients with newly diagnosed high-risk PC underwent both ¹⁸F-NaF PET/CT and ¹⁸F-PSMA-1007 PET/CT within 3 wk. The ¹⁸F-PSMA PET/CT results were initially withheld; therefore, staging and treatment decisions were based solely on ¹⁸F-NaF PET/CT. At a later time point, the ¹⁸F-PSMA PET/CT findings were revealed, and staging and treatment plans were reassessed in a multidisciplinary research setting. Differences in staging and treatment intent were analyzed using Wilcoxon signed-rank tests. Results: The metastatic stage was reclassified for 40 patients (25%) after ¹⁸F-PSMA PET/CT, with 24% classified as having a more advanced stage and 1% having a less advanced stage (P < 0.001). Lymph node metastases accounted for most changes: 30 patients (19%) with no nodal involvement on CT were found to have nodal disease on ¹⁸F-PSMA PET/CT, and the rate of extrapelvic lymph node metastases increased from 16% to 27%. Treatment plans were changed for 21 patients (13%), primarily reflecting a shift from curative to noncurative intent or toward more intensified systemic therapy (P = 0.001). Conclusion: The use of ¹⁸F-PSMA PET/CT resulted in significant metastatic stage migration and influenced treatment planning in a substantial proportion of patients.
No takes yet. Share an insight, caveat, or question.
Madsen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: